Commodore Capital LP
- SEC CIK
- 0001831942
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 31
- −5 vs. Q3 2024
- Portfolio value
- $1.36B
- −$235.7M (−14.7%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| NKTXNkarta, Inc. | COM | 351,848 | $876.1K | 0.1% | −4,310,225−92.5% | Reduced | History |
| THRDThird Harmonic Bio, Inc. | COM | 237,704 | $2.45M | 0.2% | −1,122,865−82.5% | Reduced | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 483,000 | $3.59M | 0.3% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 1,575,000 | $4.65M | 0.3% | 00.0% | Unchanged | History |
| CELCCelcuity Inc. | COM | 400,000 | $5.24M | 0.4% | −1,122,332−73.7% | Reduced | History |
| BBOTBridgeBio Oncology Therapeutics, Inc. | CL A ORD SHS | 500,000 | $5.25M | 0.4% | 00.0% | Unchanged | History |
| FRNMFreenome, Inc. | CL A ORD SHS | 750,000 | $7.63M | 0.6% | 00.0% | Unchanged | History |
| ABVXAbivax S.A. | SPONSORED ADS | 1,284,110 | $9.40M | 0.7% | 00.0% | Unchanged | History |
| APGEApogee Therapeutics, Inc. | COM | 290,000 | $13.1M | 1.0% | 00.0% | Unchanged | History |
| ORICOric Pharmaceuticals, Inc. | COM | 2,000,000 | $16.1M | 1.2% | 00.0% | Unchanged | History |
| DRUGBright Minds Biosciences Inc. | COM NEW | 500,000 | $18.0M | 1.3% | +500,000 | New | History |
| NGNENeurogene Inc. | COM | 800,000 | $18.3M | 1.3% | +600,000+300.0% | Added | History |
| IKTInhibikase Therapeutics, Inc. | COM NEW | 5,925,000 | $19.3M | 1.4% | +5,925,000 | New | History |
| CRDFCardiff Oncology, Inc. | COM | 5,384,616 | $23.4M | 1.7% | +5,384,616 | New | History |
| ORKAOruka Therapeutics, Inc. | COM | 1,419,714 | $27.5M | 2.0% | +50,000+3.7% | Added | History |
| DFTXDefinium Therapeutics, Inc. | Stock | 4,308,425 | $30.0M | 2.2% | −3,691,575−46.1% | Reduced | History |
| PHVSPharvaris N.V. | COM | 1,911,433 | $36.6M | 2.7% | 00.0% | Unchanged | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 2,218,425 | $37.2M | 2.7% | +868,425+64.3% | Added | History |
| SRRKScholar Rock Holding Corp | COM | 950,000 | $41.1M | 3.0% | +950,000 | New | History |
| VRDNViridian Therapeutics, Inc. | COM | 2,400,000 | $46.0M | 3.4% | −150,124−5.9% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,988,084 | $46.3M | 3.4% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 6,881,629 | $53.7M | 3.9% | −658,301−8.7% | Reduced | History |
| NRIXNurix Therapeutics, Inc. | COM | 3,000,000 | $56.5M | 4.1% | +1,350,000+81.8% | Added | History |
| ALKSAlkermes plc. | SHS | 2,300,000 | $66.1M | 4.8% | −600,000−20.7% | Reduced | History |
| SLNOSoleno Therapeutics Inc | COM | 1,525,000 | $68.5M | 5.0% | +265,000+21.0% | Added | History |
| VERAVera Therapeutics, Inc. | CL A | 1,958,600 | $82.8M | 6.1% | −516,400−20.9% | Reduced | History |
| ELVNEnliven Therapeutics, Inc. | COM | 4,205,000 | $94.6M | 6.9% | +105,000+2.6% | Added | History |
| XENEXenon Pharmaceuticals Inc. | COM | 2,740,000 | $107.4M | 7.9% | +40,000+1.5% | Added | History |
| NUVLNuvalent, Inc. | COM | 1,621,600 | $126.9M | 9.3% | +681,600+72.5% | Added | History |
| PCVXVaxcyte, Inc. | COM | 1,625,000 | $133.0M | 9.7% | +705,000+76.6% | Added | History |
| MRUSMerus N.V. | COM | 3,874,182 | $162.9M | 11.9% | +524,182+15.6% | Added | History |
Sold out since Q3 2024 (9)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| CLDXCelldex Therapeutics, Inc. | COM NEW | 1,618,937 | $55.0M | 3.4% | History |
| CATXPerspective Therapeutics, Inc. | COM NEW | 3,350,000 | $44.7M | 2.8% | History |
| KURAKura Oncology, Inc. | COM | 1,800,000 | $35.2M | 2.2% | History |
| RYTMRhythm Pharmaceuticals, Inc. | COM | 650,000 | $34.1M | 2.1% | History |
| ARVNArvinas, Inc. | COM | 1,200,000 | $29.6M | 1.8% | History |
| CCCCC4 Therapeutics, Inc. | COM STK | 3,410,384 | $19.4M | 1.2% | History |
| SNDXSyndax Pharmaceuticals Inc | COM | 885,000 | $17.0M | 1.1% | History |
| TILInstil Bio, Inc. | COM NEW | 150,929 | $10.2M | 0.6% | History |
| CABACabaletta Bio, Inc. | COM | 1,100,000 | $5.19M | 0.3% | History |